The New England journal of medicine, 2020-05, Vol.382 (20), p.1894-1905
2020
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- Ist Teil von
- The New England journal of medicine, 2020-05, Vol.382 (20), p.1894-1905
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2020
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- In patients with unresectable hepatocellular carcinoma, the combination of atezolizumab and bevacizumab was associated with better progression-free and overall survival outcomes, response rate, and preservation of quality of life than sorafenib. Serious toxic effects were noted in 38% of patients, similar to that seen in previous studies of these agents.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1915745Titel-ID: cdi_hal_primary_oai_HAL_hal_03574345v1
- Format
- –
- Schlagworte
- Aged, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal, Humanized - administration & dosage, Antibodies, Monoclonal, Humanized - adverse effects, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Antitumor activity, Bevacizumab, Bevacizumab - administration & dosage, Bevacizumab - adverse effects, Cancer, Cancer therapies, Carcinoma, Hepatocellular, Carcinoma, Hepatocellular - drug therapy, Clinical medicine, Female, Hepatitis, Hepatocellular carcinoma, Humans, Immunotherapy, Inhibitor drugs, Intention to Treat Analysis, Kaplan-Meier Estimate, Life Sciences, Liver cancer, Liver Neoplasms, Liver Neoplasms - drug therapy, Male, Medical prognosis, Middle Aged, Monoclonal antibodies, Patients, Programmed Cell Death 1 Receptor, Programmed Cell Death 1 Receptor - antagonists & inhibitors, Quality of Life, Solid tumors, Survival, Survival Analysis, Targeted cancer therapy, Tumors, Vascular endothelial growth factor